RARA and neoplasm: As each tumor model differs in immune and stromal composition, vasculature and genetics/transcriptomics (as demonstrated by the difference in RAR and RXR expression in tumors) it may be necessary to generate data from multiple tumor models and identify the common genes and pathways that drive CY sensitivity.